Cargando…
Review and Meta-analysis on the Impact of the ADRA2A Variant rs1800544 on Methylphenidate Outcomes in Attention-Deficit/Hyperactivity Disorder
BACKGROUND: Methylphenidate is among the most prescribed medications for treating attention-deficit/hyperactivity disorder (ADHD). However, nearly half of pediatric patients with ADHD do not respond to methylphenidate treatment. Pharmacogenetic testing can aid in identifying patients for whom methyl...
Autores principales: | Hain, Daniel T., Al Habbab, Talal, Cogan, Elizabeth S., Johnson, Holly L., Law, Rebecca A., Lewis, David J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616268/ https://www.ncbi.nlm.nih.gov/pubmed/36325160 http://dx.doi.org/10.1016/j.bpsgos.2021.07.009 |
Ejemplares similares
-
The Predictive Role of ADRA2A rs1800544 and HTR3B rs3758987 Polymorphisms in Motion Sickness Susceptibility
por: Zhang, Xinchen, et al.
Publicado: (2021) -
Methylphenidate Normalizes Frontocingulate Underactivation During Error Processing in Attention-Deficit/Hyperactivity Disorder
por: Rubia, Katya, et al.
Publicado: (2011) -
Methylphenidate use in children with attention deficit hyperactivity disorder
por: Machado, Felipe Salles Neves, et al.
Publicado: (2015) -
The Effects of Methylphenidate on Decision Making in Attention-Deficit/Hyperactivity Disorder
por: DeVito, Elise E., et al.
Publicado: (2008) -
The Effect of Methylphenidate on the Hearing of Children with Attention Deficit Hyperactivity Disorder
por: İsmi, Onur, et al.
Publicado: (2018)